Redx Pharma Plc   Report issue

For profit Phase 1 Phase 2
Founded: Macclesfield United Kingdom (2010)

Organization Overview

First Clinical Trial
2018
NCT03447470
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Redx Pharma Plc

Active Ingredients

Drugs in Phase 2 Trials (7)

Key: Redx Pharma Plc (3) Acquired (4)

denosumab (prolia) (2 trials)

ipilimumab (yervoy) (2 trials)

jtx-2011 (4 trials)

jtx-4014 (3 trials)

nivolumab (opdivo) (3 trials)

rxc004 (3 trials)

Zelasudil (2 trials)

Drugs in Phase 1 Trials (2)

Key: Redx Pharma Plc (0) Acquired (2)

jtx-8064 (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 9